Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Future Growth Projections For The Gastroparesis Drugs Market Size?

Over recent years, the market size for drugs used to treat gastroparesis has seen significant growth. Its size is projected to increase from $5.39 billion in 2024 to $5.7 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Factors that contributed to this development during the historic period include side effects from current treatments, studies into gastrointestinal motility, clinical demand, patient advocacy efforts, and assistance from regulatory bodies.

In the coming years, the market for gastroparesis drugs is projected to experience significant expansion, with an anticipated value of $7.04 billion by 2029, manifesting a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this anticipated growth within the forecast period include increasing incidences of diabetes, an aging demographic, heightened awareness and diagnostic rates, amplified expenditure in healthcare, and support from private and government sectors. Key advancements expected over the forecast period encompass progress in gastroenterology, enhanced diagnostic methods, technological breakthroughs, increased research funding and collaborative research initiatives.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Factors Are Fueling Growth In The Gastroparesis Drugs Market?

Rising instances of diabetes are predicted to drive the expansion of the gastroparesis drugs market. Known as a recurrent health concern characterized by heightened sugar levels in the blood due to inefficient insulin production or use, the escalating occurrence of diabetes can be attributed to inactive lifestyles, poor eating habits, genetic factors, urbanization, and an aging global population. This is further exacerbated by insufficient access to healthcare and increasing global obesity. Gastroparesis medications are regularly given to diabetics to relieve symptoms such as nausea, vomiting, and the slowing of gastric emptying, all typical diabetes-related issues influencing gastrointestinal mobility. These drugs aim to enhance gastric function and improve the life quality of patients suffering from diabetes-induced gastroparesis. For example, March 2024 data from the Office for Health Improvement & Disparities, a UK government department show that the proportion of individuals with type 1 diabetes undergoing all eight recommended care processes saw a 22% boost, while for type 2 diabetes the increase was 21% from March 2022 to March 2023. Moreover, the percentage achieving the target HbA1c levels hit 37.9%, the highest figure ever reported by the National Diabetes Audit (NDA). Hence, the rising prevalence of diabetes further propels the gastroparesis drugs market.

How Is The Gastroparesis Drugs Market Categorized Across Applications And Types?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

How Are Market Trends Influencing Competition In The Gastroparesis Drugs Market?

Leading firms in the gastroparesis drugs market are concentrating on developing and introducing innovative medication such as Gimoti (metoclopramide) nasal spray to gain a market advantage. Gimoti (metoclopramide) nasal spray, designed for adult gastroparesis symptom treatment, aids in stomach emptying by boosting gastrointestinal mobility. This drug avoids the gastrointestinal tract and is directly absorbed into the blood via the nasal mucosa. For instance, in April 2022, Evoke Pharma Inc., a pharmaceutical organization based in the USA, confirmed the FDA’s grant of new product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity provides Evoke with the sole distribution rights for three years from the initial approval date according to the Hatch-Waxman Act, safeguarding the product from any generic competition.

Who Are The Most Influential Companies In The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Holds The Greatest Opportunity For Gastroparesis Drugs Market Expansion?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model